Hutchison China MediTech (Chi-Med)
21st Floor, Hutchison House
10 Harcourt Road
Hong Kong
China
Tel: 852-2121-8200
Fax: 852-2121-8281
Website: http://www.hutchison-china-meditech.com/
Email: info@chi-med.com
About Hutchison China MediTech (Chi-Med)
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.YEAR FOUNDED:
2000
LEADERSHIP:
CEO: Christian Hogg
CFO: Johnny Cheng
CSO: Weiguo Su
191 articles about Hutchison China MediTech (Chi-Med)
-
BioSpace Global Roundup, July 30
7/30/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
7/28/2020
Hutchison China MediTech Limited announced that the China National Medical Products Administration has granted Priority Review status to the New Drug Application for savolitinib for the treatment of non-small cell lung cancer with MET Exon 14 skipping mutations.
-
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
7/28/2020
Hutchison China MediTech Limited and Eli Lilly and Company announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly.
-
Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China
7/24/2020
— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —
-
Chi-Med to Announce 2020 Half-Year Financial Results
6/26/2020
Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)).
-
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
6/18/2020
Hutchison China MediTech Limited announces that the US FDA has granted Fast Track Designation for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy.
-
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
6/9/2020
Hutchison China MediTech Limited announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, its 50:50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review
6/4/2020
Hutchison China MediTech Limited announces that the Independent Data Monitoring Committee of the FRUTIGA study of fruquintinib has completed a planned interim data review.
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
6/1/2020
Hutchison China MediTech Limited announces that it has held its pre-New Drug Application meeting with the U.S. Food and Drug Administration for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
-
Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
5/29/2020
Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype
-
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
5/29/2020
Hutchison China MediTech Limited announced that the New Drug Application for savolitinib for the treatment of non-small cell lung cancer with MET Exon 14 skipping mutations has been accepted for review by the China National Medical Products Administration.
-
BioSpace Global Roundup, May 28
5/28/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
5/26/2020
Hutchison China MediTech Limited and BeiGene, Ltd. announced that they have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of combining two of Chi-Med’s drug candidates, surufatinib and fruquintinib, with BeiGene’s anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.
-
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
5/14/2020
Hutchison China MediTech Limited announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming ASCO20 Virtual Scientific Program, taking place on May 29-31, 2020.
-
Chi-Med to Attend Upcoming Investor Conferences - May 08, 2020
5/8/2020
Hutchison China MediTech Limited announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time.
-
Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
4/22/2020
Hutchison China MediTech Limited announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cancer Research Virtual Annual Meeting I, taking place on April 27, 2020.
-
Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
4/17/2020
Hutchison China MediTech Limited announces that the U.S. Food and Drug Administration has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic NET in patients who are not amenable for surgery.
-
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China
3/31/2020
Hutchison China MediTech Limited has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors, in patients with advanced malignant mesothelioma.